Monday, December 19, 2022 11:53:28 AM
Recent GOSS News
- Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine • Business Wire • 05/03/2024 12:02:00 PM
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors • Business Wire • 03/12/2024 11:31:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2024 12:37:14 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 12:32:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:31:51 PM
- Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update • Business Wire • 03/05/2024 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:02:26 PM
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/08/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:11:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:04:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:02:36 PM
- Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 • Business Wire • 12/13/2023 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 10:12:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 10:09:55 PM
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/05/2023 09:01:00 PM
- Gossamer Bio Appoints Bob Smith as Chief Commercial Officer • Business Wire • 12/05/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:01:22 PM
- Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors • Business Wire • 11/29/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:01:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2023 12:07:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2023 12:07:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2023 12:07:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:01:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/14/2023 11:24:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:31:59 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM